Speakers/Panelists: From Left to Right
Top row: Dr. John Cipollo, Dr. Ying Ge, Dr. Erin Han,
Bottom row: Dr. Ventzi Hristova, Dr. Stefani Thomas, Dr. Zhengliang Wu,
Dr. John Cipollo received his Ph. D. in 2000 from the State University of New York at Albany. He performed his post-doctoral work at Boston University School of Dental Medicine under Professors Catherine Costello in mass spectrometry and Carlos Hirschberg in biochemistry. He served as Research Assistant Professor at B.U. from 2005-2007 before moving to CBER FDA where he is currently a Research Chemist and Principal Investigator of the Vaccine Structure Group. He has published over fifty scientific articles in the areas of carbohydrate structural analysis and glycomics with strong emphasis in carbohydrate mass spectrometry. Dr. Cipollo has worked extensively in the glycomics of a series of organisms including human, Caenorhabditis elegans, Entamoeba invadens, Entamoeba histolytica, and several yeast species. His current interests include the function of glycoprotein antigen interactions in adaptive and innate immunity and the impact of those functions in vaccine development and performance as revealed through investigation of molecular structure using a suite of mass spectrometric and other chemical, physiochemical and informatics based methods. Other interests include novel chemistries for improvement of polysaccharide conjugate and other glycoconjugate based vaccines. As there are few broadly accepted informatics platforms for glycomics analysis the Cipollo group has partnered with members if HIVE FDA and HIVE George Washington University to develop and make publicly available a suite of glycomics software for processing of mass spectrometry and glycan array glycomics data. Dr. Cipollo serves as a Product Specialist for CBER FDA primarily as a product reviewer for bacterial polysaccharides and polysaccharide conjugate vaccines.
Dr. Ying Ge is a Professor in the Department of Cell and Regenerative Biology and Department of Chemistry at the University of Wisconsin (UW)-Madison. She received a B.S. from Peking University (Beijing, China) and a Ph.D. from Cornell University under the joint supervision of Prof. Fred McLafferty and Prof. Tadhg Begley. After graduate school, Dr. Ge explored a career in pharmaceutical industry before she joined UW-Madison as the Director of Mass Spectrometry in the Human Proteomics Program. In 2012, Dr. Ge started her tenure-track Assistant Professor position, received tenure in 2015, and was promoted to Full Professor in 2019. Dr. Ge’s research is highly interdisciplinary that cuts across the traditional boundaries of chemistry, biology, and medicine. By creatively integrating her expertise in mass spectrometry/proteomics with cardiac biology/medicine, she aims to develop and employ novel top-down proteomics strategies in conjunction with functional studies to gain new insights into the molecular mechanisms of cardiac disease and regeneration. It is her belief that to make significant impact in molecular medicine, it is necessary to combine technological advances with functional studies and bridge the silos between basic and translational/clinical research. Recently her lab has developed a multi-pronged approach to address the challenges in top-down proteomics in a comprehensive manner. Dr. Ge is passionate about education and is currently mentoring students from chemistry, biology and medicine. At home, she enjoys spending her time with her family (taking care of her two children), gardening, cooking, and listening to music. (Ge group website: http://labs.wisc.edu/gelab/)
Dr. Erin Han is currently an NIH NRSA research fellow at the University of Colorado School of Medicine. She received her PhD at University of Colorado - Boulder where she applied novel fluorescence imaging probes and large-scale sequencing methods to study cellular signaling pathways. She is now working in Dr. Maggie Lam’s laboratory where she is developing RNA sequencing and mass spectrometry workflows to understand how alternative splicing changes proteome profile in human aging and heart diseases. One of Erin’s major career goals is to become an effective mentor to other female and underrepresented mass spectrometry scientists in the academia, and she is currently an avid trainer to undergraduate and postdoctoral trainees in the Lam lab.
Dr. Ventzi Hristova completed her Clinical Chemistry Fellowship at Johns Hopkins University School of Medicine and subsequently received her certification by the American Board of Clinical Chemistry, enabling her to oversee CLIA diagnostic testing. Following her fellowship, Ventzi joined AstraZeneca to establish a Clinical Omics Program focused on the development and implementation of innovative proteomic applications for high throughput clinical sample analysis. Integrating her experteise with patient diagnostic testing and her proteomics background, Ventzi’s work now focuses on the discovery and validation of biomarkers and therapeutic targets to support clinical studies within AstraZeneca.
Dr. Stefani Thomas is an Assistant Professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota, and she is the Associate Medical Director of the University of Minnesota Medical Center West Bank Acute Care Laboratory. She earned a BA in Biological Sciences from Dartmouth College and a PhD in Pharmaceutical Sciences from the University of Southern California. Stefani completed a postdoctoral fellowship in the laboratory of Dr. Robert Cotter in the Department of Pharmacology and Molecular Sciences at Johns Hopkins University. She then joined Dr. Hui Zhang’s laboratory as a Research Associate in the Center for Biomarker Discovery and Translation in the Johns Hopkins Department of Pathology where she led a project to develop and validate targeted mass spectrometry assays. She then completed a Clinical Chemistry postdoctoral fellowship at Johns Hopkins.
Stefani’s research laboratory at the University of Minnesota focuses on characterizing the proteome-level predictors of improved responses to PARP inhibitor therapy in ovarian cancer. She previously served as the Co-Chairperson of the Washington-Baltimore Mass Spectrometry Discussion Group, and she is currently the Secretary of the American Association for Clinical Chemistry (AACC) Proteomics and Metabolomics Division and the Chair-Elect of the AACC Midwest Section. Stefani is the recipient of an Early Career Development Award from the University of Minnesota Clinical and Translational Science Institute.
Dr. Zhengliang Wu currently works in Bio-techne/R&D Systems as a scientist and manager. He leads a team to develop research reagents for studying glycosylation. So far, he has developed over 150 active recombinant enzymes including glycosyltransferases, kinases, sulfotransferases and glycosidases. He has authored over 30 peer reviewed scientific papers, 10 patent applications and 3 issued patents. His major contributions include designing universal glycosyltransferases assays and methods for specific glycan imaging and detection.
Zhengliang obtained a bachelor’s degree in biology from Tsinghua University in 1991, and a PhD degree in molecular and cellular biology from Kent State University. His PhD work was focused on gene regulation of cholesterol metabolism. From 2000, he started postdoctoral training in MIT on the biological roles of heparan sulfate polysaccharides. Since 2006, he joined Bio-techne/R&D Systems.